Method to determine TGF-beta
US7094550B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 26, 2002 |
| Grant date | Aug 22, 2006 |
| Priority date | — |
| Expiry date | Apr 26, 2023 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I):wherein Z is C═O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.